{
  "alleleExist":false,
  "dataVersion":"v4.5",
  "diagnosticImplications":[
    {
      "abstracts":[],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "description":"",
      "levelOfEvidence":"LEVEL_Dx3",
      "pmids":[
        "28302137",
        "21390126"
      ],
      "tumorType":{
        "children":{},
        "code":"DLBCLNOS",
        "color":"LimeGreen",
        "id":490,
        "level":5,
        "mainType":{
          "id":null,
          "name":"Mature B-Cell Neoplasms",
          "tumorForm":"LIQUID"
        },
        "name":"Diffuse Large B-Cell Lymphoma, NOS",
        "parent":"MBN",
        "tissue":"Lymphoid",
        "tumorForm":"LIQUID"
      }
    },
    {
      "abstracts":[],
      "alterations":[
        "Oncogenic Mutations"
      ],
      "description":"",
      "levelOfEvidence":"LEVEL_Dx3",
      "pmids":[
        "24362818",
        "25713363"
      ],
      "tumorType":{
        "children":{},
        "code":"FL",
        "color":"LimeGreen",
        "id":286,
        "level":5,
        "mainType":{
          "id":null,
          "name":"Mature B-Cell Neoplasms",
          "tumorForm":"LIQUID"
        },
        "name":"Follicular Lymphoma",
        "parent":"MBN",
        "tissue":"Lymphoid",
        "tumorForm":"LIQUID"
      }
    }
  ],
  "diagnosticSummary":"",
  "geneExist":true,
  "geneSummary":"CREBBP, a tumor suppressor and transcriptional co-activator, is frequently inactivated in hematologic malignancies.",
  "highestDiagnosticImplicationLevel":"LEVEL_Dx3",
  "highestFdaLevel":null,
  "highestPrognosticImplicationLevel":null,
  "highestResistanceLevel":null,
  "highestSensitiveLevel":null,
  "hotspot":false,
  "lastUpdate":"10/04/2018",
  "mutationEffect":{
    "citations":{
      "abstracts":[],
      "pmids":[
        "21390130"
      ]
    },
    "description":"CREBBP truncating mutations result in various forms of C-terminally truncated CREBBP proteins. Variants resulting in the loss of the histone acetyltransferase (HAT) domain (residues 1342-1648) are likely to affect histone acetylation, target gene transcription and cell proliferation as is seen by missense mutations in this domain. Experimental studies on variants retaining the HAT domain but cleaving other C-terminal domains that bind various cofactors indicate effects on target gene expression and cellular proliferation (PMID: 21390130).",
    "knownEffect":"Likely Loss-of-function"
  },
  "oncogenic":"Likely Oncogenic",
  "otherSignificantResistanceLevels":[],
  "otherSignificantSensitiveLevels":[],
  "prognosticImplications":[],
  "prognosticSummary":"",
  "query":{
    "alteration":"H2384Tfs*12",
    "alterationType":null,
    "consequence":"frameshift_variant",
    "entrezGeneId":1387,
    "hgvs":null,
    "hugoSymbol":"CREBBP",
    "id":null,
    "proteinEnd":2384,
    "proteinStart":2384,
    "referenceGenome":"GRCh38",
    "svType":null,
    "tumorType":null
  },
  "treatments":[],
  "tumorTypeSummary":"",
  "variantExist":false,
  "variantSummary":"The CREBBP H2384Tfs*12 mutation is likely oncogenic.",
  "vus":false
}